You just read:

Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting

News provided by

Regulus Therapeutics Inc.

Nov 15, 2014, 06:00 ET